Insulet Corporation (NASDAQ:PODD) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Insulet has a consensus “Hold” rating from 27 analysts: 14 recommend buying, 11 recommend holding, and 2 recommend selling. The average 12-month price target is $195.40.
• Several analysts recently lowered their price targets, including RBC to $160, Bernstein to $175, and UBS to $150; Oppenheimer also downgraded the stock to “market perform.”
• Insulet exceeded quarterly expectations, reporting adjusted earnings of $1.66 per share versus $1.47 expected and revenue of $801.7 million, up 23.5% year over year.

Insulet Corporation (NASDAQ:PODD - Get Free Report) has been given a consensus recommendation of "Hold" by the twenty-seven analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $195.40.

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada lowered their price target on Insulet from $245.00 to $160.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Raymond James Financial reiterated an "outperform" rating and set a $180.00 price objective on shares of Insulet in a research report on Thursday, August 6th. Sanford C. Bernstein lowered their target price on Insulet from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. UBS Group dropped their target price on Insulet from $174.00 to $150.00 and set a "neutral" rating on the stock in a research report on Thursday, August 6th. Finally, Oppenheimer downgraded Insulet from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th.

Institutional Trading of Insulet

Large investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet during the fourth quarter valued at $26,000. DV Equities LLC purchased a new position in Insulet during the fourth quarter valued at $28,000. Elyxium Wealth LLC bought a new stake in Insulet during the fourth quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in Insulet in the fourth quarter worth about $29,000.

Insulet Stock Performance

Shares of PODD stock opened at $147.48 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average price of $154.45 and a 200-day moving average price of $177.72. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The firm has a market capitalization of $10.23 billion, a PE ratio of 27.57, a P/E/G ratio of 1.19 and a beta of 1.08.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the prior year, the firm earned $1.17 earnings per share. The firm's revenue for the quarter was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts expect that Insulet will post 6.51 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source